Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Jun 2009 17:15

RNS Number : 4872T
Skyepharma PLC
05 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

SkyePharma Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Delta adjustment

X

3. Full name of person(s) subject to the notification obligation: iii

D. E. Shaw & Co., L.P. 

D. E. Shaw & Co. (U.K.), Ltd. 

4. Full name of shareholder(s)  (if different from 3.):iv

N/A

5. Date of the transaction and date on which the threshold is crossed or reached: v

June 3, 2009

6. Date on which issuer notified:

June 5, 2009

7. Threshold(s) that is/are crossed or reached: vi, vii

35%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Contract for Differences ("CfD") relating to convertible bond due 2024

March 4, 2010

3,223,697

Nominal

Delta

13.85%

CfD relating to convertible bond due 2025

November 30, 2009

2,506,326

Nominal

Delta

10.77%

CfD relating to convertible bond due 2025

June 3, 2010

2,506,326

Nominal

Delta

10.77%

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,236,349

35.40%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Each of D. E. Shaw & Co., L.P. ("DESCO LP") and D. E. Shaw & Co. (U.K.), Ltd. ("DESCO UK") is notifying solely in its capacity as a discretionary investment manager. As general partner of DESCO LP, D. E. Shaw & Co., Inc. ("DESCO Inc.") is a parent undertaking of DESCO LP and DESCO UK. By virtue of David E. Shaw's position as president and sole shareholder of DESCO, Inc., which is the general partner of DESCO LP, David E. Shaw is a parent undertaking of DESCO LP and DESCO UK.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Stephen Back (Compliance Department)

15. Contact telephone number:

+1 212-478-0000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLQELFBKQBFBBL
Date   Source Headline
25th Sep 20122:31 pmRNSflutiform Launched in the UK
25th Sep 20128:00 amRNSTotal Voting Rights
25th Sep 20127:43 amRNSSubmission of New Drug Application in Japan
24th Sep 20122:53 pmRNSBond Proposals Approved
21st Sep 201210:02 amRNSflutiform Launched in Germany
18th Sep 201210:55 amRNSDirector/PDMR Shareholding
6th Sep 201210:26 amRNSHolding(s) in Company
4th Sep 20127:19 amRNSProduct Launch
23rd Aug 20127:00 amRNSRegulatory Approval
23rd Aug 20127:00 amRNSBondholder Agreement
23rd Aug 20127:00 amRNSHalf Yearly Report
8th Aug 20123:06 pmRNSHolding(s) in Company
7th Aug 20123:51 pmRNSDirector/PDMR Shareholding
27th Jul 20127:00 amRNSRAYOS (Lodotra) receives approval in U.S
17th Jul 20127:00 amRNSflutiform Receives Regulatory Approval in Germany
6th Jul 20129:25 amRNSDirector/PDMR Shareholding
3rd Jul 201211:26 amRNSRegulatory Approval
22nd Jun 20127:00 amRNSResearch Update
14th Jun 20129:56 amRNSDirector Declaration
7th Jun 20125:25 pmRNSDirector/PDMR Shareholding
16th May 20121:51 pmRNSResult of AGM
16th May 20127:00 amRNSInterim Management Statement
11th May 201210:35 amRNSDirector/PDMR Shareholding
27th Apr 20125:49 pmRNSHolding(s) in Company
27th Apr 201211:16 amRNSAnnual Information Update
23rd Apr 20123:39 pmRNSHolding(s) in Company
20th Apr 20122:23 pmRNSFlutiform Positive Outcome
20th Apr 20127:40 amRNSExparel $10m milestone payment
13th Apr 201210:29 amRNSAnnual Financial Report
11th Apr 20127:00 amRNSRespivert Contract
5th Apr 20123:36 pmRNSDirector/PDMR Shareholding
22nd Mar 20127:00 amRNSFinal Results
15th Mar 20124:44 pmRNSDirector/PDMR Shareholding
12th Mar 20127:00 amRNSNotice of Results
8th Feb 20129:00 amRNSNEW ORAL DEVELOPMENT ORGANISATION
3rd Feb 20125:28 pmRNSDirector/PDMR Shareholding
31st Jan 20128:30 amRNSDirectorate Change
10th Jan 201212:32 pmRNSDirector/PDMR Shareholding
10th Jan 20129:21 amRNSReorganisation of Swiss Operations
23rd Dec 20117:00 amRNSProduct Update
12th Dec 20115:09 pmRNSDirector Declaration
12th Dec 20113:39 pmRNSDirector/PDMR Shareholding
29th Nov 201112:16 pmRNSRegulatory Application
14th Nov 20117:00 amRNSInterim Management Statement
4th Nov 20114:15 pmRNSDirector/PDMR Shareholding
31st Oct 20112:41 pmRNSUS FDA approval of NDA for Exparel
21st Oct 20114:40 pmRNSSecond Price Monitoring Extn
21st Oct 20114:35 pmRNSPrice Monitoring Extension
18th Oct 20117:00 amRNSUPDATE ON FLUTIFORMT EUROPE
11th Oct 201110:26 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.